Aminocaproic acid decreases secondary hemorrhage after traumatic hyphema.

Abstract

Forty-eight patients (49 eyes) had nonperforating traumatic hyphema. Twenty-eight patients (28 eyes with hyphema) received oral aminocaproic acid, an antifibrinolytic agent, in a dosage of 100 mg/kg every four hours for five days, up to a maximum daily dose of 30 g. Twenty patients (21 eyes with hyphema) received placebo in an identical regimen. One eye treated with aminocaproic acid rebled; seven eyes receiving the placebo rebled. The results of this study show a statistically significant reduction in the incidence of secondary hemorrhage in the patients receiving aminocaproic acid.

• Authors: J J McGetrick, L M Jampol, M F Goldberg, M Frenkel, R G Fiscella
• Journal: Archives of ophthalmology (Chicago, Ill. : 1960) (Arch Ophthalmol) Vol. 101 Issue 7 Pg. 1031-3 (Jul 1983) ISSN: 0003-9950 [Print] United States
• PMID: 6870623 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Aminocaproates
• Antifibrinolytic Agents

Topics

• Adolescent
• Adult
• Aminocaproates (administration & dosage)
• Antifibrinolytic Agents (administration & dosage)
• Child
• Double-Blind Method
• Eye Injuries (complications)
• Female
• Humans
• Hyphema (etiology, prevention & control)
• Male
• Prospective Studies
• Random Allocation
• Recurrence
• Wounds, Nonpenetrating (complications)